BLT BLIS Technologies Limited
—Mkt Cap: —P/E: —1d ago
BLIS Technologies Limited develops and sells probiotics in New Zealand, the Asia Pacific, Europe, the Middle East, Africa, and North America. It offers BLIS K12, an oral probiotic that supports ear, nose, and throat heal…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value15.54M USD
Revenue (TTM)8.24M USD
Gross Profit5.04M USD
Net Income (TTM)469.33K USD
Revenue/Share0.01 NZD
Last Price—
Fiscal Year EndMar 2026
MR QuarterMar 2026
Employees43
CountryNZ
SectorHealthcare
IndustryBiotechnology
ISINNZBLTE0002S8
Valuation
P/E (Trailing)—
P/E (Forward)14.97
PEG—
EV/EBITDA36.14
EV/Revenue1.89
P/S2.43
P/B2.80
EPS (TTM)0.00
EPS (Forward)0.00
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin77.89%
Oper. Margin2.80%
EBITDA Margin5.22%
Profit Margin7.25%
ROE6.80%
ROA5.86%
Growth
Revenue Growth5.40%
Earnings Growth-56.30%
Cash Flow & Leverage
Operating CF-333.24K USD
CapEx (TTM)270.51K USD
FCF Margin-9.56%
FCF Yield—
Net Debt-4.52M USD
Net Debt/EBITDA-10.50
Balance Sheet
Debt/Equity0.05
Current Ratio7.56
Quick Ratio6.33
Book Value/Sh0.01 NZD
Cash/Share0.0070 NZD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NZD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.28B
Float600.50M
Insiders44.20%
Institutions0.00%
Technical
SMA 500.0235 NZD
SMA 2000.0181 NZD
Beta0.61
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)120.98K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—